ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025
Two inflammation-related genes model could predict risk in prognosis of patients with lung adenocarcinoma.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIn lung adenocarcinoma (LUAD), there remains a dearth of efficacious diagnostic studies including some inflammation-related genes to identify the LUAD subgroups with different clinical outcomes.
methodsFirst, two molecular subgroups were identified with mRNA expression profiling from The Cancer Genome Atlas (TCGA) by K-means algorithm. Gene set enrichment analysis (GSEA), immune infiltration, and Gene set variation analysis (GSVA) were applied to explore the biological functions between these two subtypes. Then, univariate and multivariate Cox regression analyses were selected to evaluate the independence of these subtypes in LUAD. Next, lasso regression was applied to identify the high-precision mRNAs to predict the subtype with favorable prognosis. Finally, a two-mRNA model was constructed using the method of multivariate Cox regression, and the effectiveness of the model was validated in a training set (n = 310) and three independent validation sets (n = 1.
resultsComprehensive genomic analysis was conducted of 310 LUAD samples and identified two subtypes associated with molecular classification and clinical prognosis: immune-enriched and non-immune-enriched subgroup. Then, a new model was developed based on two mRNAs (MS4A1 and MS4A2) in TCGA dataset and divided these LUAD patients into high-risk and low-risk subgroup with significantly different prognosis (HR = 1.644 (95% CI 1.153-2.342); p < 0.01), which was independence of the other clinical factors (p < 0.05). In addition, this new model had similar predictive effects in another three independent validation sets (HR > 1.445, p < 0.01).
conclusionsWe constructed a robust model for predicting the risk of LUAD patients and evaluated the clinical outcomes independently with strong predictive power. This model stands as a reliable guide for implementing personalized treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.